Turn Therapeutics Reports Q3 2026 Net Loss of $6.2 Million

Turn Therapeutics (TTRX) reported a Q3 2026 net loss of $6.2M, or $0.21 per share, with $10.4M in cash. It expects funds to last until Q3 2027. The company reported progress in its atopic dermatitis program and plans to start a hidradenitis suppurativa trial in early 2027. GX-03 showed positive results in a Stage 1 atopic dermatitis trial, with 59.3% of patients achieving clear or almost clear skin after four weeks.

Original reporting
Published Nov 9, 2026, 12:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 12:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Turn Therapeutics Reports Q3 2026 Net Loss of $6.2 Million — source image
Decision brief

The 30-second read

$TTRXBearishLow
01

Why it matters

The disclosed loss and cash balance suggest near‑term financing risk, but upcoming trial readouts could change the narrative.

02

Market read

Micro‑cap biotech earnings with trial updates; relevant for investors tracking early‑stage biotech risk/reward.

03

What to watch

Potential value from upcoming atopic dermatitis and hidradenitis suppurativa trial data not yet priced in.

Relevance 6/10Novelty 6/10Timing: after market close

Background

Turn Therapeutics is a clinical‑stage biotech focused on dermatology treatments. The Q3 2026 filing is its first earnings release for the year.

Company-level read

Ticker impact

$TTRXBearishMedium confidence
Context

Turn Therapeutics disclosed Q3 2026 results with a net loss of $6.2M and cash runway to Q3 2027, plus trial updates.

Expected impact

likely downward pressure as investors price in the loss and limited cash runway

Evidence & confidence

Micro‑cap biotech earnings that miss expectations typically trigger sell‑offs, especially with a small cash balance.

Market effects

Highlights ongoing risk in early‑stage biotech sector and may dampen sentiment for similar dermatology‑focused firms.

Limited to US biotech investors; no broader regional effect.

Minimal global impact; primarily relevant to niche biotech investors.

Counterpoint

Some investors may view the cash runway to 2027 as a runway for upcoming trial readouts and could see upside.

Key entities

  • Turn Therapeutics

    Clinical‑stage biotech developing GX-03 for skin disorders.

  • Robert R. Redfield, M.D.

    Appointed chief scientific officer, former CDC director.

Related articles

$TTRXMed

Turn Therapeutics Provides Corporate Updates and Reports Third Quarter 2026 Financial Results

Turn Therapeutics Inc. (TTRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Turn Therapeutics Provides Corporate Updates and Reports Third Quarter 2026 Financial Results Completed GX-03 Stage 1/Phase 2a Trial: 59.3% of GX-03 Patients Achieved Clear or Almost Clear Skin After Four Weeks, Compared with 30.4% Receiving Vehicle Larger Phase 2b A

$TTRXMed

WBB Securities upgrades Turn Therapeutics stock rating to hold

WBB Securities upgraded Turn Therapeutics (TTRX) to Hold from Sell, setting a $10.00 price target. The stock has fallen from $16.45 but is up over 200% in six months. WBB expects Phase 2 trial results in 2026, but sees challenges for small-cap life science firms. Lucid Capital Markets initiated coverage with a Buy rating and $24.00 target, citing GX-03's potential.

$TTRXMedAI 8/10

Turn updates investor presentation; Phase 2 AD topline due Q1 2027, $10.3M cash runways into Q3 2027

Turn Therapeutics updated its investor presentation, highlighting GX-03 clinical progress and a $10.3M cash balance as of June 30, 2026. The company expects Phase 2 topline results for atopic dermatitis in Q1 2027 and has a cash runway into Q3 2027. Key milestones include an FDA meeting in Q4 2026 and Phase 3 initiations in 2027. The presentation also details safety and efficacy signals, financials, and IP status.

$TTRXMed

Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results

Turn Therapeutics Inc. (TTRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results Interim Analysis Supports Expansion of GX-03 Phase 2 Study to a Broader Population of Atopic Dermatitis Patients, Including Patients with Moderate-to-Severe Lesions but Low

$TTRXMed

Turn Therapeutics stock rises on expanded dermatitis trial By Investing.com

Turn Therapeutics (TTRX) shares rose 3.8% premarket after expanding its GX-03 Phase 2 atopic dermatitis trial to a broader EASI severity population. The company completed an interim analysis and said efficacy was seen in mild-to-moderate patients (EASI 1.1–7.0), with 71.4% vs 33.3% vehicle achieving Week 4 vIGA-AD success. Final design targets ~120–135 patients; no treatment-related serious AEs reported.